An Act to promote transparency and prevent price gouging of pharmaceutical drug prices

This Massachusetts bill aims to increase transparency and curb high drug prices by requiring pharmaceutical companies and pharmacy benefit managers to share more information about pricing factors. It mandates that these entities provide early notice to the state when new drugs are submitted for approval and requires the state commission to conduct annual studies on how specific drugs impact healthcare spending. Additionally, the bill expands the commission's authority to hear testimony on manufacturer rebates and discounts, while also adjusting how the commission covers its own operating costs by assessing fees directly on the drug industry.